Learn From Real-world Experience
Using clonoSEQ for Routine Clinical Care
Many clinicians are aware of the prognostic value of measurable residual disease (MRD) in lymphoid cancers and the clinical data supporting the clonoSEQ® Assay as a highly sensitive and robustly validated method to assess MRD. Yet questions remain: What do MRD results mean for an individual patient? How do clonoSEQ results inform clinician and patient decision-making? How is clonoSEQ used in routine clinical practice?
As the provider of the only FDA-cleared assay for MRD assessment in chronic lymphocytic leukemia (CLL), multiple myeloma, and B-cell acute lymphoblastic leukemia (B-ALL) which is used by clinicians nationwide, Adaptive has access to a unique and large collection of HCP cases, patient testimonials, and internal testing data, all of which help to illustrate the real-world applications of MRD testing in these lymphoid cancers. These resources provide an opportunity to learn from leading experts who are incorporating clonoSEQ into clinical practice decisions, as well as from patients who’ve seen firsthand how MRD results can inform and empower them.
Test Your clonoSEQ Knowledge
How much do you know about clonoSEQ MRD testing in clinical practice?
How clinicians are using clonoSEQ in routine practice
clonoSEQ is FDA-cleared for patients with CLL, myeloma, and B-ALL. clonoSEQ may be used to inform care decisions such as reducing or stopping treatment, re-initiating treatment, or assessing treatment response. Explore case studies on how clonoSEQ is used to assess treatment response or inform clinical care decisions to reduce or stop treatment or re-initiate treatment.
MRD-Based Risk Assessment in Multiple Myeloma to Inform Maintenance Discontinuation
Leading expert views on the role of MRD in patient care
The body of evidence supporting MRD assessment in routine patient care is growing. Leading experts share their views on MRD, the evolving role of MRD testing in lymphoid cancers, and insights on how MRD results influence clinical practice decisions.
Ola Landgren, MD, PhD
Dr. Ola Landgren discusses the prognostic value of MRD and its important role in myeloma due to the deep responses now available.
Hervé Avet-Loiseau, MD, PhD
Dr. Hervé Avet-Loiseau explores prognostic factors in myeloma treatment and the future of MRD.
The patient perspective on MRD
Shared decision-making between patients and care teams improves trust and quality of life. Patients offer their stories and insights on the role of MRD testing in their personal treatment journeys.
Tim: A Myeloma Patient Discusses His Views on the Importance of MRD
As a patient with high-risk myeloma, Tim shares his experiences and insights on what MRD testing means for patients.
When experience builds to evidence: Peer-reviewed real-world evidence analysis
Data from clinical trials has demonstrated the prognostic value of MRD within controlled research settings. Do those findings hold true in routine clinical practice? Institutions have published their experience with clonoSEQ and demonstrated how MRD assessment in a real-world setting has the same predictive power as that seen in clinical trials.
Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma
In this study published in Blood Advances, clinicians from UCSF analyzed data from their real-world experience assessing MRD in both newly diagnosed and relapsed/refractory myeloma patients.
The Adaptive experience: observations and analysis of real-world clonoSEQ results
As the leading provider of clinical NGS MRD testing in the U.S., Adaptive Biotechnologies has an unparalleled ability to draw insight from our internal data. Leveraging this unique dataset, we can illustrate how, when and for which patient types MRD testing is currently being used by clinicians. These data also enable publication of novel findings regarding the depth and duration of the response that clonoSEQ-tested patients are achieving.
Real-World Minimal Residual Disease (MRD) Assessment and Trends Using clonoSEQ in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma.
This study in the Journal of the National Comprehensive Cancer Network provides a unique perspective on understanding patient MRD testing patterns in the real world.
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.